Literature DB >> 28470341

"The simplest explanation is usually the correct one" - Can Occam's razor be applied for diffuse astrocytoma and paradoxical amino acid metabolism?

Egesta Lopci1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28470341     DOI: 10.1007/s00259-017-3708-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  12 in total

1.  Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.

Authors:  Osamu Manabe; Naoya Hattori; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Shunsuke Terasaka; Hiroyuki Kobayashi; Hiroaki Motegi; Tohru Shiga; Keiichi Magota; Noriko Oyama-Manabe; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

2.  O-methylation and decarboxylation of alpha-methyldopa in brain and spinal cord: depletion of S-adenosylmethionine and accumulation of metabolites in catecholaminergic neurones.

Authors:  C M Lo; M L Kwok; R J Wurtman
Journal:  Neuropharmacology       Date:  1976-07       Impact factor: 5.250

3.  Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas?

Authors:  A Verger; D Taieb; E Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-27       Impact factor: 9.236

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas.

Authors:  A Verger; Ph Metellus; Q Sala; C Colin; E Bialecki; D Taieb; O Chinot; D Figarella-Branger; E Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-14       Impact factor: 9.236

6.  Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma.

Authors:  Nathalie L Jansen; Bogdana Suchorska; Vera Wenter; Christine Schmid-Tannwald; Andrei Todica; Sabina Eigenbrod; Maximilian Niyazi; Jörg-Christian Tonn; Peter Bartenstein; Friedrich-Wilhelm Kreth; Christian la Fougère
Journal:  J Nucl Med       Date:  2015-01       Impact factor: 10.057

7.  Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography.

Authors:  Natsuki Shinozaki; Yoshio Uchino; Kyosan Yoshikawa; Tomoo Matsutani; Azusa Hasegawa; Naokatsu Saeki; Yasuo Iwadate
Journal:  J Neurosurg       Date:  2011-01-07       Impact factor: 5.115

8.  Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results.

Authors:  Thierry Jacob; Dany Grahek; Nassima Younsi; Khaldoun Kerrou; Nicolas Aide; Françoise Montravers; Sonia Balogova; Cecile Colombet; Virginie De Beco; Jean N Talbot
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-10       Impact factor: 9.236

9.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.

Authors:  Zachary J Reitman; Genglin Jin; Edward D Karoly; Ivan Spasojevic; Jian Yang; Kenneth W Kinzler; Yiping He; Darell D Bigner; Bert Vogelstein; Hai Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-02       Impact factor: 12.779

Review 10.  Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

Authors:  Nanne K Kloosterhof; Linda B C Bralten; Hendrikus J Dubbink; Pim J French; Martin J van den Bent
Journal:  Lancet Oncol       Date:  2010-07-07       Impact factor: 54.433

View more
  1 in total

1.  A kinetic solution for the paradoxical difference between F-Dopa and methionine.

Authors:  Masashi Kameyama; Yumi Umeda-Kameyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-12       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.